« Previous Release | Next Release »

August 23, 2006

Mayne Pharma's Purchase of SuperGen's North American Oncology Products Completes

DUBLIN, Calif. and MELBOURNE, Australia, Aug. 23 /PRNewswire/ -- Mayne Pharma Limited (ASX: MYP) and SuperGen, Inc. (Nasdaq: SUPG) today announce that the proposed acquisition of the North American rights to SuperGen's Nipent® (pentostatin for injection) and SurfaceSafe™, as communicated on 22 June 2006, has completed.

Mayne Pharma will pay a total maximum consideration of US$34 million inclusive of approximately US$14 million at completion. Remaining payments are contingent on key events and product performance.

    For further information about Mayne Pharma, please contact:

    Investor Contact                    Media Contact
    Andrew Rowe                         Teresa La Thangue
    Vice President Investor Relations   Media Relations Manager
    Ph: +44 (0) 20 7420 8426            Ph: + 44 (0) 20 7420 8479
    Mobile: +44 7920 598 353            Mobile: +44 7920 598 352
                                        or
                                        Sue Cato
                                        Ph: +61 293602021
                                        Mobile: +61 419282319

    For further information about SuperGen, please contact:

    Timothy L Enns                      Sharon Weinstein
    SuperGen, Inc.                      Noonan Russo
    Tel: (915) 560 0100 x 111           Tel: (212) 845 4271
    tenns@SuperGen.com                  Sharon.weinstein@eurorscg.com

    Notes to editors:

    About SuperGen

Based in Dublin, California, SuperGen is a pharmaceutical company dedicated to the discovery, acquisition, rapid development and commercialization of therapies for solid tumors and hematological malignancies. SuperGen's portfolio includes Orathecin™ (rubitecan) capsules, an investigational drug intended for the treatment of pancreatic cancer, Nipent® (pentostatin for injection), Mitomycin, SurfaceSafe® cleaner, and a number of preclinical products being developed as inhibitors of aurora-A, tyrosine kinase and DNA methyltransferase. For more information about SuperGen, please visit http://www.supergen.com/ .

About Mayne Pharma

Mayne Pharma Limited is a specialty pharmaceutical company focused on developing, manufacturing and selling a comprehensive range of products to oncology customers in more than 65 countries around the world. The company seeks to augment its growth by accessing additional marketed or development- stage products either through acquisition or partnership. Mayne Pharma generated sales of more than $US 500 million in its financial year ended 30 June 2005 and is listed on the Australian Stock Exchange under the symbol 'MYP'. For more information about Mayne Pharma, please visit http://www.maynepharma.com .

This press release contains "forward-looking" statements within the meaning of Section 21A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, and is subject to the safe harbor created thereby. These forward-looking statements include statements regarding the ability of the proposed transaction to strengthen SuperGen's financial position and enable SuperGen to commercialize its other products. Such statements are just predictions and involve risks or uncertainties such that actual results and performance may differ materially. Factors that might cause such a difference include (1) the failure of the parties to consummate the proposed transaction, (2) failure by Mayne to achieve the revenue milestones, resulting in SuperGen's failure to earn the deferred payments under the agreement. These and other risks are detailed from time to time in SuperGen's periodic filings with the Securities and Exchange Commission, including the report on Form 10-K for the fiscal year ended December 31, 2005 and on Form 10-Q for the quarter ended June 30, 2006. These forward-looking statements are made only as of the date hereof, and we disclaim any obligation to update or revise the information contained in any such forward-looking statements, whether as a result of new information, future events or otherwise.

Nipent® is a registered trademark of SuperGen, Inc.


SOURCE SuperGen, Inc.
CONTACT: Investors: Andrew Rowe, Vice President Investor Relations, +44-20-7420-8426, Mobile: +44-7920-598-353, or Media: Teresa La Thangue, Media Relations Manager, +44-20-7420-8479, Mobile: +44-7920-598-352, or Sue Cato, +61-293602021, Mobile: +61-419282319, all for Mayne Pharma Limited; Timothy L Enns, of SuperGen, Inc., +1-915-560-0100 x 111, tenns@SuperGen.com; Sharon Weinstein of Noonan Russo, +1-212-845-4271, Sharon.weinstein@eurorscg.com, for SuperGen, Inc.
Web site: http://www.supergen.com
http://www.maynepharma.com
(SUPG)


Close window | Back to top

Copyright 2013 Astex Pharmaceuticals